See the DrugPatentWatch profile for ingrezza
Is Ingrezza approved to treat Huntington's disease?
Ingrezza, also known as valbenazine, is a medication approved by the FDA to treat the symptoms of tardive dyskinesia, a side effect of long-term antipsychotic treatment, not Huntington's disease [1]. However, there is ongoing research into its potential use in the treatment of Huntington's disease.
What does Huntington's disease involve?
Huntington's disease is a rare, inherited disorder characterized by progressive damage to the brain, leading to cognitive decline, motor dysfunction, and psychiatric symptoms [2]. While there is no cure for Huntington's disease, various medications and therapies aim to manage its symptoms and slow disease progression.
Research into Ingrezza's potential in Huntington's disease treatment
Preclinical studies suggest that valbenazine, the active ingredient in Ingrezza, may have beneficial effects on the symptoms of Huntington's disease, such as motor dysfunction and cognitive impairment [3]. These studies demonstrate the potential of valbenazine to cross the blood-brain barrier and modulate the dopamine and serotonin systems, which are affected in Huntington's disease [4].
Clinical trials and development
Although Ingrezza is not approved for Huntington's disease treatment, clinical trials are ongoing to evaluate its efficacy and safety in this indication. These studies aim to assess the potential benefits of valbenazine on motor and cognitive symptoms in patients with Huntington's disease. The results of these trials will determine whether Ingrezza can be repurposed as a treatment for Huntington's disease.
Conclusion
Ingrezza, also known as valbenazine, is not currently approved to treat Huntington's disease, but ongoing research and clinical trials may lead to its approval in the future. The potential benefits of valbenazine in this indication are promising and require further investigation.
Sources:
[1] FDA approval of Ingrezza for tardive dyskinesia, available at.
[2] What is Huntington's disease? available at.
[3] Preclinical studies on valbenazine's effects on Huntington's disease, published in Neuropharmacology, available at.
[4] Mechanisms of action of valbenazine in the context of Huntington's disease, published in ACS Chemical Neuroscience, available at.